### New Diabetes Treatments and Technologies in 2016 #### Afrezza Sanofi has ended its agreement with MannKind to manufacture and sell Afrezza, an inhaled insulin. MannKind will now take over production and is looking for new partners. #### Sanofi Sanofi's new U-300 basal insulin Toujeo is on the market. They are also focusing on GLP-1 agonists and GLP-1/basal insulin combo drugs, with Lyxumia and Lixilan in the pipeline. #### Novo Nordisk Novo's long-lasting basal insulin Tresiba is competing with Toujeo. They are also developing a faster-acting version of Novolog, expected to be ready in 2016. #### Eli Lilly Eli Lilly's new basal insulin Basaglar, a less-expensive version of Lantus, will be available by the end of 2016. #### Dario Meter The Dario meter, a compact device that connects to smartphones for blood glucose monitoring, has been approved by the FDA and will be available in 2016. #### Dexcom Dexcom plans to file for its next-gen G6 CGM, which offers 10 days of wear and improved accuracy, with hopes for a 2016 launch. #### Medtronic Medtronic is working on the Minimed 640G system, which can predict and prevent low blood sugar. They are also developing the Minimed 670G, a hybrid closed-loop system. #### Abbott Abbott's FreeStyle Libre Flash Glucose Monitoring system, which combines fingerstick testing and CGM, is expected to come to the U.S. in 2016. #### Insulet Insulet is working on a new PDM product and a U-500 OmniPod for higher-concentrated insulin, with clinical trials running through 2016. #### Animas Animas plans to launch the Calibra Finesse Patch Pump, a bolus-only insulin patch, in 2016. #### BD BD's new Flowsmart insulin infusion set aims to reduce occlusion errors and will be available in 2016. #### Eli Lilly's Nasal Glucagon Eli Lilly acquired Locemia, a nasal glucagon for emergency blood sugar boosts, expected to be filed with the FDA by mid-2016.